Key facts
- Alnylam Pharmaceuticals and Inceptive have formed a strategic collaboration.
- The partnership will leverage artificial intelligence for drug discovery.
- The goal is to accelerate the development of RNAi therapeutics.
Alnylam Pharmaceuticals has announced a collaboration with Inceptive, a company focused on artificial intelligence. This partnership is set to integrate advanced AI technologies into Alnylam's development pipeline for RNA interference (RNAi) therapeutics. The primary objective of this collaboration is to expedite the process of discovering and creating novel RNAi-based treatments. By applying AI, Alnylam aims to enhance the efficiency and speed of its therapeutic development efforts.